Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Relationship between splitting and amplification of 11q13.3-q13.4 and clinical features of primary ESCC tumors

From: Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors

Clinical features Splitting Amplification
  Frequency P value Frequency P value
Gender
 Male 47.2% (50/106) 0.089 a 86.2% (94/109) 1.000 a
 Female 28.6% (8/28)   89.3% (25/28)  
Age
 < 60 47.8% (33/69) 0.274 87.1% (61/70) 1.000 a
 ≥ 60 38.5% (25/65)   86.6% (58/67)  
Tumor size
 T1, T2 50.0% (10/20) 0.511 85.0% (17/20) 0.728 a
 T3, T4 42.1% (48/114)   87.2% (102/117)  
Lymph node metastasis
 N0 30.2% (19/63) 0.004 79.4% (50/63) 0.022 a
 N1 54.9% (39/71)   93.2% (69/74)  
Stage
 I, IIa 29.3% (17/58) 0.004 79.3% (46/58) 0.039 a
 IIb, III, IV 53.9% (41/76)   92.4% (73/79)  
Differentiation
 G1 40.7% (11/27) 0.762 b 85.2% (23/27) 0.118 b
 G2 41.7% (30/72)   91.9% (68/74)  
 G3 48.6% (17/35)   77.8% (28/36)  
  1. a Fisher’s test.
  2. b Kruskal–Wallis test.
  3. The P value which is not labeled with “a” or “b” is assessed by χ2 test.
Back to article page